Article

Is the Arginine-Nitric Oxide Pathway Involved in the Pathogenesis of Schizophrenia?

Department of Psychiatry, Gaziantep University, Ayıntap, Gaziantep, Turkey
Neuropsychobiology (Impact Factor: 2.26). 02/2003; 47(2):61-5. DOI: 10.1159/000070010
Source: PubMed

ABSTRACT

The reciprocal regulation of arginase and nitric oxide synthase (NOS) in L-arginine-metabolizing pathways has been demonstrated. There are various evidences of the role of the nitric oxide (NO) in several neuropsychiatric disorders including schizophrenia. However, there is no study which has investigated the role of arginase as an important part of the arginine regulatory system affecting NOS activity in schizophrenia. This study aims to investigate arginase, manganese (Mn) and total nitrite levels (a metabolite of NO) and their relationship to the arginine-NO pathway in patients with schizophrenia. Arginase activities, Mn and total nitrite levels were measured in plasma from 46 patients with schizophrenia and 32 healthy control subjects. Plasma arginase activities and Mn were found to be significantly lower and total nitrite level higher in patients with schizophrenia compared with controls. Our results suggest that the arginine-NO pathway is involved in the pathogenesis of schizophrenia.

Download full-text

Full-text

Available from: Hasan Herken, Apr 21, 2014
  • Source
    • "Schizophrenia is a chronic and severe psychiatric disease that affects about 1% of the population and causes disability[1,2]. There are genetic and biochemical studies focused on the etiopathogenesis of schizophrenia[3]. Current diagnostic approaches for schizophrenia are based on patient interviews, which entail a subjective assessment of clinical symptoms. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated whether prolidase activity has a diagnostic test value in schizophrenia and assessed the relation between prolidase activity and sociodemographic-clinical characteristics of patients with schizophrenia. Fifty patients with schizophrenia (diagnosed as schizophrenia according to DSM-V criteria) and 50 healthy volunteers were included in this study. Case and control groups had a similar distribution in age, sex, body mass index (BMI), and smoking status. Serum prolidase activity was measured in both groups and was determined to be significantly higher in the patient group (509.706±41.918) compared to the control group (335.4±13.6; t=6.231; p=0.0001). A cut-off point of 392.65U/L prolidase was determined for diagnostic measures from the plotted ROC curve. The area under the ROC curve was 1.000, which was significant (p<0.0001). Higher values were assigned as the disease state. Both positive predictive value (PPV) and negative predictive value (NPV) were 100% at the cut-off point of 392.650U/L. The prolidase levels of the control group were all below the cut-off point. There were no statistically significant differences between the two groups with regard to age, gender, or BMI (p>0.05), and no correlation was found between mean prolidase activity and age of onset of the disease, family history, disease duration, number of hospitalizations, subtypes of schizophrenia, PANSS scores or sub-scores, CGI-S scores, S-A scale scores, and the antipsychotic treatment (p>0.05). The results of this study indicate that serum prolidase activity may be a useful diagnostic test for schizophrenia; however, further studies are needed to verify this.
    Full-text · Article · Dec 2015 · Neuroscience Letters
  • Source
    • "They include such elements as copper (Cu), manganese (Mn), selenium (Se), zinc (Zn), and iron (Fe). The idea that abnormal levels of these elements are related to schizophrenia is not recent (Blaustein and Ickowicz, 1983; Gould et al., 1983; Yanik et al., 2003; Grabrucker et al., 2011). However, this hypothesis has been raised based on studies done in non-neural tissues (blood, hair, and liquor) or postmortem neural tissues, which may not be a bona fide representation of what occurs in the brain of schizophrenic patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia has been considered a devastating clinical syndrome rather than a single disease. Nevertheless, the mechanisms behind the onset of schizophrenia have been only partially elucidated. Several studies propose that levels of trace elements are abnormal in schizophrenia; however, conflicting data generated from different biological sources prevent conclusions being drawn. In this work, we used synchrotron radiation X-ray microfluorescence spectroscopy to compare trace element levels in neural progenitor cells (NPCs) derived from two clones of induced pluripotent stem cell lines of a clozapine-resistant schizophrenic patient and two controls. Our data reveal the presence of elevated levels of potassium and zinc in schizophrenic NPCs. Neural cells treated with valproate, an adjunctive medication for schizophrenia, brought potassium and zinc content back to control levels. These results expand the understanding of atomic element imbalance related to schizophrenia and may provide novel insights for the screening of drugs to treat mental disorders.
    Full-text · Article · Apr 2014 · Schizophrenia Research
  • Source
    • "Human genetic research has identified schizophrenia risk genes encoding neuronal NOS (Shinkai et al., 2002; Reif et al., 2006; Cui et al., 2010). Furthermore, plasma arginase activity has been found to be decreased in schizophrenic patients (Yanik et al., 2003), and the serum levels of L-ornithine positively correlate with the disease duration (Tomiya et al., 2007). Agmatine and polyamines putrescine, spermidine and spermine have also been suggested to play a role in the aetiology and pathology of schizophrenia (Fiori and Turecki, 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Phencyclidine (PCP), a non-competitive N-methyl-D-aspartate glutamate receptor antagonist, induces schizophrenic symptoms in healthy individuals, and altered arginine metabolism has been implicated in schizophrenia. The present study investigated the effects of a single subcutaneous injection of PCP (2, 5 or 10 mg/kg) on arginine metabolism in the sub-regions of the hippocampus and prefrontal cortex in male young adult Sprague-Dawley rats. Animals' general behavior was assessed in the open field apparatus 30 min after the treatment, and the brain tissues were collected at the time point of 60 min post-treatment. Behaviourally, PCP resulted in reduced exploratory activity in a dose-dependent manner, and severe stereotype behavior and ataxia at the highest dose. Neurochemically, PCP significantly altered the nitric oxide synthase and arginase activities, the L-arginine, agmatine, spermine, glutamate and GABA levels, and the glutamine/glutamate and glutamate/GABA ratios in a dose-dependent and/or region-specific manner. Cluster analyses showed that L-arginine and its main metabolites L-citrulline, L-ornithine and agmatine formed distinct groups, which changed as a function of PCP mainly in the hippocampus. Multiple regression analysis revealed significant neurochemical-behavioural correlations. These results demonstrate, for the first time, that a single acute administration of PCP affects animals' behavior and arginine metabolism in the brain.
    Full-text · Article · Feb 2014 · Neuropharmacology
Show more